GlassScriptPhysician profile
Stephen R Bell
NPI 1184704181
$2,002.77
in general payments reported to CMS, 2019-2025
24 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $419 · 2021: $92.85 · 2022: $331 · 2023: $358 · 2024: $430 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $459.06 | 2021-2025 | |
| Lilly USA, LLC | $332.72 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $234.96 | 2019-2023 | |
| Amgen INC. | $127.60 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $99.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $95.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ucb, INC. | $89.51 | 2024 | |
| Nestle Healthcare Nutrition INC. | $78.61 | 2022-2023 | |
| Corcept Therapeutics | $69.08 | 2020 | |
| Allergan, INC. | $64.45 | 2020 | |
| Pfizer INC. | $53.54 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.96 | 2019 | |
| Abbvie INC. | $40.49 | 2022-2023 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $35.33 | 2020 | |
| Glaxosmithkline, LLC. | $25.16 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $25.03 | 2020 | |
| Inspire Medical Systems, INC. | $17.47 | 2023 | Inspire |
| Kowa Pharmaceuticals America, INC. | $17.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.04 | 2020 | |
| Genzyme Corporation | $15.71 | 2023 | |
| Axsome Therapeutics, INC. | $14.96 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $14.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.